Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Impact of an Intensified Thromboprofylaxis Protocol in COVID-19

16 maggio 2020 aggiornato da: Jessa Hospital

Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study

The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

Panoramica dello studio

Descrizione dettagliata

Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.

On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.

We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.

Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.

Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.

Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.

Additional data collection

Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:

  • Demographics: i.e age, gender, BMI, Apache II score (to predict mortality)
  • Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other
  • Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc…
  • Laboratory results of all standard parameters measured
  • Treatment: antiviral agents, antibiotics, etc…
  • Complications: shock, heart failure, sepsis, stroke, etc…
  • Ventilation: method, PEEP, FiO2, P/F ratio ..
  • SOFA score (Sequential Organ Failure Assessment)
  • Radiological findings: pneumonia, ground-glass opacity..

Tipo di studio

Osservativo

Iscrizione (Effettivo)

72

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Hasselt, Belgio, 3500
        • Jessa Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

N/A

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione di probabilità

Popolazione di studio

All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.

Descrizione

Inclusion Criteria:

- All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.

Exclusion Criteria:

- Patients younger than 18 years old.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Before or control group
All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
After or intervention group
On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
2 week mortality
Lasso di tempo: 2 weeks after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
2 weeks after admission at ICU

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
incidence of venous thromboembolism
Lasso di tempo: during ICU stay up till 3th of May 2020
the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
1 week mortality
Lasso di tempo: 1 week after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
1 week after admission at ICU
3 week mortality
Lasso di tempo: 3 weeks after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
3 weeks after admission at ICU
1 month mortality
Lasso di tempo: 1 month after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
1 month after admission at ICU
incidence of kidney failure
Lasso di tempo: during ICU stay up till 3th of May 2020
incidence of acute kidney failure in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
incidence of continuous renal replacement therapy (CRRT)
Lasso di tempo: during ICU stay up till 3th of May 2020
incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
lowest PaO2/FiO2 (P/F) ratio
Lasso di tempo: during ICU stay up till 3th of May 2020
evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
highest Sequential Organ Failure Assessment (SOFA) score
Lasso di tempo: during ICU stay up till 3th of May 2020
evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
length of stay
Lasso di tempo: during ICU and hospital stay up till 3th of May 2020
evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU
during ICU and hospital stay up till 3th of May 2020
highest bilirubin
Lasso di tempo: during ICU stay up till 3th of May 2020
evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
highest ( AST
Lasso di tempo: during ICU stay up till 3th of May 2020
evaluation of the highest AST level in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
highest Aspartaat-Amino-Transferase (ALT)
Lasso di tempo: during ICU stay up till 3th of May 2020
evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 maggio 2020

Completamento primario (Effettivo)

15 maggio 2020

Completamento dello studio (Effettivo)

15 maggio 2020

Date di iscrizione allo studio

Primo inviato

16 maggio 2020

Primo inviato che soddisfa i criteri di controllo qualità

16 maggio 2020

Primo Inserito (Effettivo)

19 maggio 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 maggio 2020

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 maggio 2020

Ultimo verificato

1 maggio 2020

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi